batabulin

Batabulin is a small molecule antitumor agent that covalently and selectively binds to specific β-tubulin isotypes (β1, β2, and β4) at a conserved cysteine residue. This binding disrupts microtubule polymerization in cancer cells, leading to cytoskeletal collapse, cell cycle arrest at the G2/M phase, and induction of apoptosis. Batabulin has demonstrated efficacy against both sensitive and multidrug-resistant tumor xenografts in preclinical models. It was investigated for several cancers including breast cancer, colorectal cancer, glioma (including anaplastic astrocytoma and glioblastoma multiforme), hepatocellular carcinoma, and non-small cell lung cancer. Clinical development was discontinued after studies showed limited clinical activity in some indications[1][3][5][6].

Other names

batabulin sodiumAMG-67 (salt)2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene